Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Current Research and Training Grants

Selected current research and training grants of the faculty and fellows in the Division of Infectious Diseases are listed below. There are opportunities for fellows to participate in these research projects, as well as with investigators at Rockefeller University or Memorial Sloan-Kettering Institute.

  1. Optimizing Clinical Use of Polymyxin B: Teaching an Old Drug to Treat Superbugs. DP Calfee (site PI). NIH-NIAID. 2015- 2020.
  2. Harnessing single cell epigenome-wide profiling of myeloid cells to compare and contrast Alzheimer’s from HIV-associated cognitive dysfunction L Ndhlovu NIH r01 ag063846 2020-2025
  3. Development of brain organoids to study the impact of hiv-1, drugs of abuse and aging on cognitive impairment N Nixon L Ndhlovu NIH r01da052027 2020-2025
  4. Effects of human galectin-9 on the CNS HIV reservoir sk pillai, j joseph, L Ndhlovu NIH r01mh112457 2016-2021
  5. Effects of HIV SIV on unconventional t cells in immunity to m. Tuberculosis in pre adolescents c scanga, j miller, L Ndhlovu r01ai142662 2019-2024
  6. Host glycomic modulation of HIV-associated neuro-inflammation during viral suppression mm Abdel, M Wong, L Ndhlovu r01ns117458 2020-2024
  7. Research Training in Infectious Diseases. RM Gulick; MJ Glesby; K Marks; C Nathan. NIH T32 AI07613. 1999-2025.
  8. Weill Cornell Medical College—New Jersey Medical School Clinical Trials Unit (AIDS Clinical Trials Group and HIV Prevention Trials Network). RM Gulick; MJ Glesby; K Marks; M Vogler; TJ Wilkin. NIH U01 AI69419. 2007-2021.
  9. CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional Characteristics. RB Jones. NIH R01 AI131798. 2017-2022.
  10. CTI-mediated elimination of replication competent vs. Defective HIV proviruses from natural latent reservoirs: roles of antigen specificity and functional characteristics RB Jones r01ai131798 2018-2022
  11. Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs RB Jones r01ai147845 2019-2024
  12. Role of translational polymerases in genome diversification of the malaria parasite. NIH/NIAID. L. Kirkman NIH RO1 AI 146153. 2019-24.
  13. Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication (BELIEVE). DF Nixon, RB Jones. NIH 5UM1AI126617. 2016-2021.
  14. Elimination of HIV using herv specific t cells D Nixon r01ai076059 2019-2020
  15. HIV induced anti-cancer herv immunity in prostate, breast and colon cancers D Nixon r01ca206488 2016-2021
  16. GHESKIO HIV Clinical Trials Unit (CTU). JW Pape; DW Fitzgerald. U01 AI 069421. 2006-2020.
  17. Research Training for AIDS-related Multi-Drug Resistant Tuberculosis in Haiti. JW Pape; DW Fitzgerald; WD Johnson. D43 TW 010062. 2015 – 2020.
  18. Clinical Scholar in Microbiology and Infectious Diseases. M Satlin. William Randolph Hearst Foundation. 2018-2021.
  19. Antibacterial Resistance Leadership Group. Co-Investigator MJ Satlin (PI: Vance Fowler; Henry Chambers). NIH- NIAID UM1AI104681. 2019-2026.
  20. Metagenomic Profiling of Urinary Cell-Free DNA to Monitor Urinary Tract Infections after Kidney Transplantation. Co-Investigator MJ Satlin (PI: Iwijn de Vlaminck). NIH-NIAID R01AI151059. 2020-2025.
  21. Detection of Impending Infections in Immunocompromised Cancer Patients. Co-Investigator M Satlin (PI: Justin Cross). Starr Cancer Consortium. 2020-2021.
  22. Multiplex PCR Characterization of Gastrointestinal Pathogens in Immunosuppressed Patients. Co-Investigator MJ Satlin (PI: John Lee). BioFire Diagnostics, LLC: Investigator-initiated grant. 2018-2020.
  23. Clinical studies of investigational antiviral agents in transplantation and oncology. C Small; R Soave; S Jacobs; and M Satlin. 2016-2020.
  24. Screening for Resistant Enteric Bacteria to Personalize Infection Prevention Strategies in Neutropenic Patients. PI: Satlin. NIH-NIAID R01AI151038. 2020 -2024.
  25. Burroughs Wellcome Fund Physician-Scientist Institutional Award)\Weill Cornell Medicine Physician-Scientist Academy1020043 K. Rhee 2019 – 2024
  26. NIH/NIAID Tri-I Training Program in Metabolomics R25AI140472 K. Rhee 2019 - 2024
  27. NIH/NIAID Molecular, Biomedical, and In Vivo Analysis of High and Low Transmission Mtb Strains, U19AI111276 K. Rhee, subcontract 2019 – 2024
  28. NIH/NIAID Omics for TB: Response to Infection and Treatment; U19AI135976 K. Rhee, subcontract 2018 – 2023
  29. Harrington Scholar Innovator Award; Pantothenamides Against Tuberculosis: Selective Inhibitors of the Mycobacterium Tuberculosis Tubercle HDI193972-01 K. Rhee 2020 – 2021
  30. NIH/NIAID Tri-institutional Tuberculosis Research Unit: Persistence and Latency: U19AI111143 K. Rhee, Project leader 2014 - 2021
  31. Bill & Melinda Gates Foundation: Metabolomics to Identify Synergistic TB targets: BMGF 204250 K. Rhee 2020 - 2023
  32. NIH/NIAID Pathway Analysis in Tuberculosis: P01AI143575 K. Rhee, Core leader 2020 – 2025
  33. Tri-Institutional Tuberculosis Research Unit: Latency and Persistence. C Nathan (PI); KY Rhee (project leader). U19AI111143 NIH/NIAID. 2014-2021.
  34. Preclinical studies of the mechanisms, safety, efficacy, and pharmacokinetics of investigational antibacterial and antifungal agents in preclinical in vitro and in vivo model systems. T Walsh; V Petraitis; R Petraitiene; and M Satlin. 2016-2020.
  35. Bacteriophage Therapy against Multidrug Resistant Bacteria Causing Serious Wound Infections T. Walsh ; US Dept of Defense (DOD) January 2019 – June 2020
  36. Clinical studies of investigational antifungal and antibacterial agents in in transplantation and oncology. T Walsh; C Small; D Helfgott; S Jacobs; R Petraitiene; M Satlin; R Soave. 2016-2020.

Infectious Diseases

Roy M. Gulick, M.D., Chief

Avi Bueno, Administrator
Tel: (212) 746-4914
Fax: (212) 746-8675

Infectious Diseases Fellowship Program

Matthew S. Simon, M.D., Program Director
Rosy Priya L. Kodiyanplakkal, M.D, Assistant Program Director
Ole Vielemeyer, M.D., Assistant Program Director

Marisol Valentin, Program Coordinator
1300 York Avenue, A-421
New York, NY 10065
Tel: (212) 746-7602
Fax: (212) 746-8675